---
title: "Endovia plans FDA pre-submission conference for CannEpil Z filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297517810.md"
description: "Endovia Health Sciences Inc. plans to submit a pre-submission package to the FDA for its product CannEpil Z in the coming week. The filing aims to secure an FDA pre-submission conference to discuss the proposed regulatory and development pathway for the product."
datetime: "2026-08-31T12:32:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297517810.md)
  - [en](https://longbridge.com/en/news/297517810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297517810.md)
generator: "portal-rs"
---

# Endovia plans FDA pre-submission conference for CannEpil Z filing

-   Endovia plans an FDA “CannEpil Z” submission in the coming week. \* The filing targets an FDA pre-submission conference to discuss the product’s proposed regulatory and development pathway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endovia Health Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310830PRIMZONEFULLFEED9818239) on August 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [EDVA.US](https://longbridge.com/en/quote/EDVA.US.md)

## Related News & Research

- [Palvella completes rolling FDA NDA submission for QTORIN rapamycin in microcystic lymphatic malformations](https://longbridge.com/en/news/297509688.md)
- [Tempus AI (TEM) Could Be 18% Below Fair Value As FDA Clearance Lands](https://longbridge.com/en/news/297426690.md)
- [Bonesupport says FDA extends deadline for Cerament V additional data package to October](https://longbridge.com/en/news/297131100.md)
- [CYTK: Aficamten showed robust efficacy and manageable safety in non-obstructive HCM, with FDA submission planned](https://longbridge.com/en/news/297306529.md)
- [NeuralCloud appoints former FDA reviewer Mehmet Kosoglu as head of regulatory affairs](https://longbridge.com/en/news/297641596.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**